Activity Description
Antibody-drug conjugates (ADCs) are an emerging chemotherapy class with significant ocular side effects. This activity reviews ADC mechanisms, corneal toxicity pathophysiology, and characteristic slit lamp findings, enabling clinicians to identify and manage ADC-associated ocular adverse events including blurred vision, dry eye, and pseudomicrocysts.
Sponsored by
The Fundingsland Group, LLC is a COPE-Approved Administrator.
This activity, COPE Activity Number 132797, is accredited by COPE for continuing education for optometrists. This course is approved for 0.25 hours of CE.
Course # 104055-PH
Activity #: 132797
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Release Date: 5-29-2026
Expiration Date: 05-28-2027
Target Audience
This accredited educational activity is designed for optometrists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from AbbVie.
Faculty
